

CNS SPECTRUMS[®]

THE INTERNATIONAL JOURNAL OF NEUROPSYCHIATRIC MEDICINE

ORIGINAL RESEARCH

Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: *Results of a Double-Blind, Randomized, Placebo-Controlled Study*

R. Weisler, J. M. Joyce, L. McGill, A. Lazarus, J. Szamosi, and H. Eriksson

Validation of the University of São Paulo Sensory Phenomena Scale: *Initial Psychometric Properties*

M. C. Rosario, H. S. Prado, S. Borcato, J. B. Diniz, R. G. Shavitt, A. G. Hounie, M. E. Mathis, R. S. Mastroso, P. Velloso, E. A. Perin, V. Fossaluzza, C. A. Pereira, D. Geller, J. Leckman, and E. Miguel

Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder: *Integrative Analysis of Four Double-Blind, Randomized Clinical Trials*

S. G. Kornstein, D. Li, Y. Mao, S. Larsson, H. F. Andersen, and G. I. Papakostas

TRENDS IN PSYCHOPHARMACOLOGY

Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: *Storyboarding a Presentation and the Rule of Small Multiples*

S.M. Stahl and R.L. Davis

IN SESSION

Narcolepsy

J. M. Siegel



**RESENTFUL
DEFIANT ANGRY
ARGUMENTATIVE
LOSES TEMPER
IRRITABLE¹**

ADHD with oppositional symptoms

As important to treat as it is to discuss

Oppositional symptoms—the missing piece of the ADHD symptom discussion

40% to 60% of children with ADHD present with oppositional symptoms.²⁻⁵ Many parents, however, are not aware of the relationship of these symptoms and ADHD or how they can exacerbate the disorder.⁶

How many of these patients are in your practice?

Initiating frank and open discussions with parents and using diagnostic tools that include oppositional symptoms may further refine a comprehensive treatment plan for ADHD with oppositional symptoms.

40% to 60%
of children with ADHD
present with oppositional
symptoms²⁻⁵

Visit www.ADHDplus.com to find out how you can start the discussion to help manage oppositional symptoms and address what was once left unsaid.

References: 1. Conners CK. Conners 3™—parent. North Tonawanda, NY: Multi-Health Systems Inc; 2008. 2. Elia J, Ambrosini P, Berrettini W. ADHD characteristics: I. Concurrent co-morbidity patterns in children & adolescents. *Child Adolesc Psychiatr Ment Health*. 2008;2(1):15. 3. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry*. 1999;56:1073-1086. 4. Attention-deficit disorders with oppositionality and aggression. In: Brown TE, ed. *Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adults*. Arlington, VA: American Psychiatric Publishing, Inc; 2000. 5. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. *J Am Acad Child Adolesc Psychiatry*. 1996;35:1193-1204. 6. Findling RL, Connor DF, Wigal T, Eagan C, Onofrey MN. A linguistic analysis of in-office dialogue among psychiatrists, parents, and child and adolescent patients with ADHD [published online ahead of print September 2, 2008]. *J Atten Disord*. 2008. <http://jadsagepub.com/cgi/content/abstract/1087054708323002v1>.

EDITORS

EDITOR IN CHIEF

Andrew A. Nierenberg, MD
Harvard Medical School
Boston, MA

FOUNDING EDITOR

Eric Hollander, MD
Institute of Clinical Neuroscience
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Cape Town
Cape Town, South Africa

ASIA

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Susan G. Kornstein, MD
Maria Conceicao Rosario, MD, PhD
Richard Weisler, MD

FIELD EDITOR

Michael Trimble, MD, FRCP, FRPsych

COLUMNISTS

Uriel Halbriech, MD
Stefano Pallanti, MD, PhD
Thomas E. Schlaepfer, MD
Stephen M. Stahl, MD, PhD
Dan J. Stein, MD, PhD

CME COURSE DIRECTOR

James C.-Y. Chou, MD

SUPPLEMENT EDITOR

Joseph Zohar, MD

EDITORIAL ADVISORY BOARD

Lenard Adler, MD
New York University Medical School
New York, NY

Dennis S. Charney, MD
Mount Sinai School of Medicine
New York, NY

Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA

John Geddes, MD, FRCPsych
University of Oxford
Oxford, United Kingdom

Mark S. George, MD
Medical University of South Carolina
Charleston, SC

Daphne Holt, MD
Massachusetts General Hospital
Charlestown, MA

Andres M. Kanner, MD
Rush University
Chicago, IL

Siegfried Kasper, MD
University of Vienna
Vienna, Austria

Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France

Sarah H. Lisanby, MD
Columbia University
New York, NY

Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN

Mario F. Mendez, MD
University of California, Los Angeles
Los Angeles, CA

Philip Mitchell, MB BS, MD, FRANZCP,
FRCPsych
University of New South Wales
Sydney, Australia

Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom

Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico

Stefano Pallanti, MD, PhD
University of Florence
Florence, Italy

Katharine Phillips, MD
Brown Medical School
Providence, RI

Diego A. Pizzagalli, PhD
Harvard University
Boston, MA

Mark H. Pollack, MD
Massachusetts General Hospital
Charlestown, MA

Mark Rapaport, MD
University of California, Los Angeles
Los Angeles, CA

Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA

Peter P. Roy-Byrne, MD
University of Washington School of Medicine
Seattle, WA

Gerard Sanacora, MD
Yale University
New Haven, CT

Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA

Thomas E. Schlaepfer, MD
University of Bonn
Bonn, Germany

Jordan W. Smoller, MD, ScD
Massachusetts General Hospital
Charlestown, MA

Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, CA

Stephen Strakowski, MD
University of Cincinnati
Cincinnati, OH

Scott Stroup, MD, MPH
University of North Carolina, Chapel Hill
Chapel Hill, NC

Norman Sussman, MD
New York University Medical School
New York, NY

Pierre N. Tariot, MD
University of Arizona
Phoenix, AZ

Michael E. Thase, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

Madhukar H. Trivedi, MD
University of Texas Southwestern Medical Center
Dallas, TX

Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, TX

Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands

Carlos A. Zarate, Jr., MD
National Institute of Mental Health
Bethesda, MD

PUBLICATION STAFF

CEO & PUBLISHER

Darren L. Brodeur

VP, MANAGING EDITOR

Christopher Naccari

VP, HUMAN RESOURCES

Kimberly A. Brodeur

SENIOR PROJECTS EDITOR

Deborah Hughes Levy

SENIOR EDITOR-PRIMARY PSYCHIATRY

Dena Croog

EDITOR-CNS SPECTRUMS

Virginia Jackson

ASSOCIATE EDITOR

Lonnie Stoltzfoos

ASSISTANT EDITOR

Carlos Perkins, Jr.

SENIOR ACQUISITIONS EDITOR

Lisa Arrington

EDITORIAL INTERN

Amanda Cuomo

CME DEVELOPMENT MANAGERS

Annette Schwind
Shelley Wong

ASSISTANT-CME ADMINISTRATION

Sonny Santana

ART DIRECTOR

Derek Oscarson

GRAPHIC DESIGNER

Michael J. Vodiako

CHIEF FINANCIAL OFFICER

John Spano

ACCOUNTING INTERN

Stephanie Spano

SALES & EVENT COORDINATOR

Kimberly Schneider

INFORMATION TECHNOLOGY

Clint Bagwell Consulting

CORPORATION COUNSEL

Lawrence Ross, Esq.
Bressler, Amery, and Ross

MBL
communications

Publishers of **PRIMARY PSYCHIATRY**
The Largest Peer-Reviewed Psychiatric Journal in the Nation


CNS SPECTRUMS
The International Journal of Neuropsychiatric Medicine

Psychiatry Weekly
The Leading News Service From Primary Psychiatry and Psychiatry Weekly

ADS
The Summit on Alzheimer's Disease
ALZHEIMER'S DISEASE SUMMIT

THE NEXT GENERATION OF BLACK BOOKS

NOW AVAILABLE



ORDER YOUR BLACK BOOK COPIES ONLINE

**The Black Book of Psychotropic Dosing and Monitoring
The Black Book of Insomnia
The Black Book of Fibromyalgia
The Black Book of ADHD
The Black Book of Alzheimer's Disease**

Spiral bound print versions of each Black Book are now available for only \$9.99 plus S & H, and interactive e-versions for your desktop and/or smart phone are coming soon.

To order, please visit Customer Service at www.cnsspectrums.com

Please contact the publisher, dlb@mbcommunications.com, for more information or call 212-328-0800 x266

MBL
communications

Publishers of

PRIMARY PSYCHIATRY
The Largest Peer Reviewed Psychiatric Journal in the Nation

CNS SPECTRUMS
The International Journal of Neuropsychiatric Medicine

Psychiatry Weekly
The Leading News Service from Primary Psychiatry® and Physician's Weekly®

ADS
ALZHEIMER'S DISEASE SUMMIT

EDITORIAL**284 Uncertainty and Practical Reasoning in Clinical Psychiatry and Neurology**Andrew A. Nierenberg, MD, *Harvard Medical School***CLINICAL UPDATES IN NEUROPSYCHIATRY**

- 286**
- *FDA Approves Lamotrigine Orally Disintegrating Tablets for the Treatment of Bipolar I Disorder*
 - *FDA Approves Risperidone Long-Acting Injection for Maintenance Treatment of Bipolar I Disorder*
 - *FDA Approves Iloperidone for the Treatment of Schizophrenia*
 - *Neurologist/Patient Communication Needs Improving*
 - *Alzheimer's Disease Patients Suffering from Delirium Have Faster Cognitive Decline*

TRENDS IN PSYCHOPHARMACOLOGY**288 Applying the Principles of Adult Learning to the Teaching of Psychopharmacology: Storyboarding a Presentation and the Rule of Small Multiples**Stephen M. Stahl, MD, PhD, *University of California—San Diego*; and Richard L. Davis, *Arbor Scientia***IN SESSION****295 Jerome M. Siegel, PhD**
• **Narcolepsy****ORIGINAL RESEARCH****299 Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study**Richard Weisler, MD, *University of North Carolina—Chapel Hill*; Mark Joyce, MD, and Lora McGill, MD, *CNS Healthcare*; Arthur Lazarus, MD, MBA, *AstraZeneca*; and Johan Szamosi, MSc, and Hans Eriksson, MD, PhD, MBA, *AstraZeneca (Sweden)***315 Validation of the University of São Paulo Sensory Phenomena Scale: Initial Psychometric Properties**Maria Conceição Rosario, MD, PhD, and Helena Silva Prado, BA, MS, *Federal University of São Paulo*; Sonia Borcato, BA, Juliana Belo Diniz, MD, Roseli Gedanki Shavitt, MD, PhD, Ana Gabriela Hounie, MD, PhD, and Maria Eugênia Mathis, BA, MS, *Clinical Hospital at the University of São Paulo Medical School*; Rosana Savio Mastroso, BA, Patricia Velloso, BA, Eduardo Allende Perin, MD, Victor Fossaluzza, BA, *Federal University of São Paulo*; Carlos Alberto Pereira, PhD, *Clinical Hospital at the University of São Paulo Medical School*; Daniel Geller, MD, *Harvard Medical School*; James Leckman, MD, *Yale University School of Medicine*; and Euripedes Miguel, MD, PhD *Clinical Hospital at the University of São Paulo Medical School***326 Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder: Integrative Analysis of Four Double-Blind, Randomized Clinical Trials**Susan G. Kornstein, MD, *Virginia Commonwealth University*; Dayong Li, PhD, *Forest Research Institute*; Yongcai Mao, PhD, Sara Larsson, PhD, and Henning F. Andersen, MSc, *H. Lundbeck A/S*; and George I. Papakostas, MD, *Harvard Medical School*

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc., 333 Hudson Street, 7th Floor, New York, NY 10013. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to *CNS Spectrums*, 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$195; in-training \$85. For subscriptions: Tel: 212-328-0800; Fax: 212-328-0600; Web: www.cns-spectrums.com. Single issues: \$15 – E-mail ks@mbcommunications.com

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., *CNS Spectrums*, LLC, or the editorial advisory board.

This month's issue of *CNS Spectrums*, as well as a host of educational resources, enduring materials, and archived issues, is available at www.cns-spectrums.com.

Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of *CNS Spectrums*, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher.



Copyright © 2009 by MBL Communications, Inc. All rights reserved. Printed in the United States.



DID SHE TELL YOU ABOUT HER POOR METABOLISM?

AmpliChip CYP450 Test

The **first FDA-cleared test** that **reliably detects variations** in the **CYP2D6 and CYP2C19 genes** with greater than **99% accuracy** for detection and genotype call rate.¹

With the AmpliChip CYP450 Test results, you may achieve improved patient outcomes by using your patients' metabolic profiles as a guide to medication and dosing.

For more information, visit www.amplichip.us.

1. AmpliChip CYP450 Test Package
Insert as of 03/20/2007

AMPLICHIP is a trademark of Roche.
©2007 Roche Diagnostics.
All rights reserved. 472-39211-0108

AMPLI[©]CHIP